JUN 16, 2021 7:00 AM PDT

The paradigm of lung cancer: from therapy selection to resistance monitoring

Sponsored by: Agilent
  • Antonio Marchetti, Ph.D

    Full Professor of Pathology and Director of the Inter-Departmental Center of Advanced Molecular Diagnostics and Innovative Therapies, University of Chieti-Pescara, Italy

Event Date & Time
Date:  June 16, 2021
Time: 7:00am (PDT),  10:00am (EDT)
Non-small cell lung cancer (NSCLC) has become an important example of precision medicine among solid tumor malignancies. Next-generation sequencing panels have proven to be powerful tools for multi-marker analysis and here, we describe the use of an all-in one lung panel to detect mutations in lung tumor samples. In addition, we have been able to identify specific mutations in liquid biopsies—such as CNVs and gene fusions—that are important drivers of resistance in NSCLC.
Learning Objectives
  • Explain how lung cancer treatment has changed in the context of personalized medicine
  • Describe the approach of detecting DNA fusions using the SureSelect hybrid capture-based targeted NGS
  • Share experience in implementing an automated NGS workflow with the Magnis NGS Prep System and SureSelect Cancer All-In-One panels


For Research Use Only. Not for use in diagnostic procedures.
Webinars will be available for unlimited on-demand viewing after live event.

You May Also Like
Loading Comments...
  • See More